NCT06609356 Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes
| NCT ID | NCT06609356 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Vanderbilt University Medical Center |
| Condition | Type 1 Diabetes Mellitus |
| Study Type | INTERVENTIONAL |
| Enrollment | 27 participants |
| Start Date | 2025-07-03 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 27 participants in total. It began in 2025-07-03 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to understand the heart and blood sugar health benefits of using an adjunctive therapy to lower high insulin levels in people with type 1 diabetes. The investigators will also look at people with a specific type of diabetes called Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY) and those without diabetes to help interpret the results. The investigators will use a medication that helps the body get rid of sugar, called and SGLT2 inhibitor, with the goal to reduce the body's insulin requirements. The investigators believe this could lead to better heart and blood sugar health, including a better response to insulin and more available nitric oxide, a gas that helps blood vessels function well. The investigators will compare heart and blood sugar health risk factors in participants with type 1 diabetes, participants with Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), and non-diabetic healthy volunteers under two conditions: high insulin levels typical of type 1 diabetes and normal insulin levels typical of the other two groups.
Eligibility Criteria
Inclusion Criteria: Age: 18-60 years BMI: 18-28 kg/m² Weight: ≥ 50 kg T1DM Participants: Duration of T1DM: 1-30 years HbA1c: 5.7-7.5% Insulin Therapy: Using automated insulin delivery GCK-MODY Participants: HbA1c: 5.7-7.5% Genetic Confirmation: Positive GCK sequencing Control Participants: HbA1c: less than 5.5% \*\* Exclusion Criteria: Severe Hypoglycemia: ≥1 episode in the past 3 months Comorbidities: * Any hospital admissions for diabetic ketoacidosis in the past 6 months * SBP greater than 140 mmHg and DBP greater than 100 mmHg * eGFR by MDRD equation of less than 60 mL/min/1.73 m² * AST or ALT greater than 2.5 times ULN * Hct less than 35% Medications: * Any antioxidant vitamin supplement within 2 weeks before the study * Any systemic glucocorticoid * Antipsychotics * Atenolol, Metoprolol, Propranolol * Niacin * Any thiazide diuretic * Any oral contraceptive pill with greater than 35 mcg ethinyl estradiol * Growth hormone * Any immunosuppressant * Antihypertensive * Any antihyperlipidemic Other: * Pregnancy * Tanner stage less than 5 * Peri- or post-menopausal women * Active smoker T1DM Participants: Medications: Any diabetes medication except insulin C-peptide: greater than 0.7 ng/mL (fasting) GCK-MODY Participants: None specific
Contact & Investigator
Daniel J Moore, MD, PhD
PRINCIPAL INVESTIGATOR
Vanderbilt University Medical Center
Frequently Asked Questions
Who can join the NCT06609356 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Type 1 Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06609356 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06609356 currently recruiting?
Yes, NCT06609356 is actively recruiting participants. Contact the research team at metabolism@vumc.org for enrollment information.
Where is the NCT06609356 trial being conducted?
This trial is being conducted at Nashville, United States.
Who is sponsoring the NCT06609356 clinical trial?
NCT06609356 is sponsored by Vanderbilt University Medical Center. The principal investigator is Daniel J Moore, MD, PhD at Vanderbilt University Medical Center. The trial plans to enroll 27 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.